Humacyte Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	1.57	-	-	1.57	1.26	1.49
Revenue Growth (YoY)	-	-	-	23.91%	-15.29%	-75.90%
Cost of Revenue	75.37	88.6	76.55	63.26	61.34	54.08
Gross Profit	-73.8	-88.6	-76.55	-61.7	-60.08	-52.59
Selling, General & Admin	30.89	25.8	20.39	22.88	21.13	12.01
Operating Expenses	30.89	25.8	20.39	22.88	21.13	12.01
Operating Income	-104.69	-114.4	-96.94	-84.58	-81.21	-64.6
Interest Expense	-10.67	-9.28	-6.6	-6.2	-4.35	-2.2
Interest & Investment Income	2.94	4.1	5.47	2.63	0.02	0.28
Other Non Operating Income (Expenses)	21.39	3.92	-0.26	0.42	0.06	-
EBT Excluding Unusual Items	-91.03	-115.66	-98.33	-87.73	-85.48	-66.52
Merger & Restructuring Charges	-0.7	-	-	-	-0.05	-
Other Unusual Items	54.76	-33.05	-12.44	75.77	59.06	-
Pretax Income	-36.97	-148.7	-110.78	-11.97	-26.48	-66.52
Net Income	-36.97	-148.7	-110.78	-11.97	-26.48	-66.52
Net Income to Common	-36.97	-148.7	-110.78	-11.97	-26.48	-66.52
Shares Outstanding (Basic)	143	118	103	103	40	6
Shares Outstanding (Diluted)	143	118	103	103	40	6
Shares Change (YoY)	27.11%	14.56%	0.36%	157.82%	593.25%	-71.34%
EPS (Basic)	-0.26	-1.26	-1.07	-0.12	-0.66	-11.54
EPS (Diluted)	-0.26	-1.26	-1.07	-0.12	-0.66	-11.54
Free Cash Flow	-106.4	-99.69	-75.59	-72.18	-81.41	-55.89
Free Cash Flow Per Share	-0.74	-0.84	-0.73	-0.70	-2.04	-9.69
Operating Margin	-6663.85%	-	-	-5404.35%	-6429.77%	-4332.66%
Profit Margin	-2353.22%	-	-	-764.54%	-2096.36%	-4461.70%
Free Cash Flow Margin	-6772.95%	-	-	-4611.95%	-6445.76%	-3748.22%
EBITDA	-97.32	-107.21	-89.22	-76.37	-72.97	-56.25
D&A For EBITDA	7.37	7.19	7.72	8.21	8.24	8.35
EBIT	-104.69	-114.4	-96.94	-84.58	-81.21	-64.6

Updated Nov 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q